Industry Sponsorship and Authorship of Clinical Trials Over 20 Years

  title={Industry Sponsorship and Authorship of Clinical Trials Over 20 Years},
  author={Susan S Buchkowsky and Peter J. Jewesson},
  journal={Annals of Pharmacotherapy},
  pages={579 - 585}
BACKGROUND The pharmaceutical industry has become a major source of funding for biomedical research. Our general observation is that pharmaceutical industry employees are appearing with increasing frequency as coauthors of clinical trial publications. OBJECTIVE To characterize clinical trial funding, reporting, and sources; investigate author—industry affiliation; and describe clinical outcome trends over time. METHODS We reviewed 500 randomly selected clinical trials published in 5 influential… 

Figures and Tables from this paper

Industry sponsorship and research outcome.
The analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments.
The Impact of Industry Funding on Randomized Controlled Trials of Biologic Therapies
Industrial-funded trials investigating biologic therapies are more likely to yield statistically significant positive outcomes and use placebo comparators when compared to non-industry-funded biologic therapy trials in high-impact medical journals.
Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.
Authors who perform key roles in the conception and design, analysis, and interpretation, or reporting of oncology clinical trials are more likely than authors who do not perform such roles to have financial ties to industry.
Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology.
The interpretation of recently published phase III cancer trials by their authors or by editorialists was not influenced by financial relationships or industry sponsorship, which may have led to more integrity in cancer research reporting.
Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.
Industry funding was not associated with a higher likelihood of positive outcomes of published RCTs of drug therapy for RA, and industry-funded R CTs performed significantly better than non-industry-fundedRCTs in terms of reporting the use of some key methodologic quality measures.
Association of author's financial conflict of interest with characteristics and outcome of rheumatoid arthritis randomized controlled trials.
FCOI reporting in RA drug RCT authors is common and temporally increasing and a remarkable temporal increase in reporting of honoraria/consultation fees receipt, research grant, and stock ownership was seen.
A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design
No significant relationship was found between industry sponsorship and use of randomization in trial design in this cross-sectional study of 477 HIV and HCV drug treatment trials registered with


Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Investigating whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support found systematic bias favours products which are made by the company funding the research.
Source of funding and outcome of clinical trials
  • R. Davidson
  • Medicine, Psychology
    Journal of general internal medicine
  • 1986
Few trials supported by pharmaceutical manufacturers favored traditional therapy; some reasons for this finding may include selection of drugs likely to be proven efficacious, Type II errors (false-negative studies), and fear of discontinuation of funding should such studies be submitted.
Scope and impact of financial conflicts of interest in biomedical research: a systematic review.
Original, quantitative studies on the extent, impact, and management of financial conflicts of interest in biomedical research are reviewed to show a statistically significant association between industry sponsorship and pro-industry conclusions.
Managing conflicts of interest in the conduct of clinical trials.
To preserve the integrity ofResearch and to protect the welfare of human subjects who enroll in trials, physicians should have adequate training in the conduct of research and be familiar with the ethics of research.
Publication bias and clinical trials.
Funding source, trial outcome and reporting quality: are they related? Results of a pilot study
It is not known whether the absence of significant associations between funding source, trial outcome and reporting quality reflects a true absence of an association or is an artefact of inadequate statistical power, reliance on voluntary disclosure of funding information, a focus on trials recently published in the top medical journals, or some combination thereof.
Bias in reporting clinical trials.
  • A. Bardy
  • Medicine
    British journal of clinical pharmacology
  • 1998
Substantial evidence of selective reporting was detected, since trials with positive outcome resulted more often in submission of final report to regulatory authority than those with inconclusive or negative outcomes.
Pharmaceutical advertising revenue and physician organizations: how much is too much?
Potential financial conflicts of interest arising from pharmaceutical advertisements in medical journals may be substantial and the impact on professional societies' financial independence and behavior is unknown.
Uneasy alliance--clinical investigators and the pharmaceutical industry.
The past 10 years have seen the spectacular growth of a new research model, and commercially oriented networks of contract-research organizations (CROs) and site-management organizations (SMOs) have altered.